𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Liver transplantation for hepatocellular carcinoma in patients without underlying liver disease: A systematic review

✍ Scribed by Houben, Karin W. ;McCall, John L.


Publisher
Wiley (John Wiley & Sons)
Year
1999
Tongue
English
Weight
53 KB
Volume
5
Category
Article
ISSN
1074-3022

No coin nor oath required. For personal study only.

✦ Synopsis


Liver resection is the treatment of choice for hepatocellular carcinoma (HCC) occurring in the absence of underlying chronic liver disease. Orthotopic liver transplantation (OLT) is reserved for patients with unresectable disease but remains controversial. The aim of this study was to review the published literature on OLT for HCC in patients without coexisting chronic liver disease. A Medline-based search identified 126 patients reported in 16 papers over the last 32 years. One third had fibrolamellar HCC (FL-HCC), and two thirds had non-FL-HCC. Recurrence data were given in 55 patients of whom 27 had tumor recurrence. Seventy-five percent of the recurrences occurred within the first 2 years after OLT, although recurrences were reported up to 72 months after OLT for FL-HCC. The 5-year survival rate was greater in patients who underwent transplantation for FL-HCC than for non-FL-HCC (39.4% and 11.2%, respectively). There was insufficient information available to determine the influence of tumor size, distribution, stage, and vascular invasion on survival, although most patients in whom tumor characteristics were specified had advanced disease. This study indicates that FL-HCC carcinoma is a more favorable indication for OLT than non-FL-HCC in patients without underlying liver disease, although more detailed prognostic information is required to improve patient selection.


πŸ“œ SIMILAR VOLUMES


Sorafenib therapy in patients with hepat
✍ Ian A. Rowe πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 277 KB πŸ‘ 1 views

The team of Liu et al. generated endoderm-derived human induced pluripotent stem (iPS) cells from primary hepatocytes. 1 However, they generated human iPS cells by using viral transgenes. 1 Clinical applications of human iPS cells require avoiding viral transgenes. On the other hand, the reprogrammi

Survival after liver transplantation in
✍ J Figueras; E Jaurrieta; C Valls; C Benasco; A Rafecas; X Xiol; J Fabregat; T Ca πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 154 KB πŸ‘ 1 views

Cumulative recurrence after surgical resection for hepatocellular carcinoma (HCC) is very high. Several retrospective analyses have shown that liver transplantation was more effective than resection for patients with HCC at early tumor stages. Consequently, in January 1990, we decided to prospective

Expanded criteria for liver transplantat
✍ Mauricio Silva; Angel Moya; Marina Berenguer; Fernando Sanjuan; Rafael LΓ³pez-And πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 189 KB πŸ‘ 1 views

Orthotopic liver transplantation (OLT) selection for patients with hepatocellular carcinoma (HCC) is a matter of debate. The Milan criteria (MC) have been largely adopted by the international community. The main aim of this study was to evaluate the survival rates and recurrence probabilities of a n

A new priority policy for patients with
✍ Fabio Piscaglia; Valeria Camaggi; Matteo Ravaioli; Gian Luca Grazi; Matteo Zanel πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 188 KB πŸ‘ 1 views

The best prioritization of patients with hepatocellular carcinoma (HCC) waiting for liver transplantation under the model for end-stage liver disease (MELD) allocation system is still being debated. We analyzed the impact of a MELD adjustment for HCC, which consisted of the addition of an extra scor